Where is the company headed?

Quote

anonymous

Guest
I have been here 10 years and I have very much enjoyed my time at this company. The people here are truly wonderful. I have to wonder where we are going though? Our #s are way way down from our days in the past. Some of that was just bloated silly pods, with 6 people selling spiriva (Dumb). However, it does seem that our #s keep getting smaller and smaller every year. With Spiriva gone soon, and Pradaxa as well, one has to think that we are in for even more of a reduction sometime soon? I'm not sure if anyone has friends in house? I have a few close friends in the AoB, and nothing to do with COVID, they say it is a ghost town in there. #s are incredibly small. The #s of support teams are tiny compared to what they used to be. If you look at our pipeline, there's nothing for several years (at a minimum) outside of expanded indications for existing products. Nothing more than an educated guess and listening to what others are saying, but seems like we are headed for respiratory being completely gone in a few years, and CV/Met having more of a merge/reduction? It appears like OFEV and Jardiance are the only games in town right now. Would love to see more products on the near horizon for folks to be happy about. Keep your head low and sell I suppose, not much else you can do. Curious on others thoughts?
 




I have heard the company is going over to only specialized products upon the sunset of Jardiance. Which has some time-
Maybe another oncology product and very narrow therapeutic areas like OFEV encapsulates.
Not sure how the bio similar market is looking though as soon as a determination is made on how to successfully utilize- shifts will be in that direction - BIPI will likely wait and see how other companies approach such market then approach
 




anonymous said:
I have been here 10 years and I have very much enjoyed my time at this company. The people here are truly wonderful. I have to wonder where we are going though? Our #s are way way down from our days in the past. Some of that was just bloated silly pods, with 6 people selling spiriva (Dumb). However, it does seem that our #s keep getting smaller and smaller every year. With Spiriva gone soon, and Pradaxa as well, one has to think that we are in for even more of a reduction sometime soon? I'm not sure if anyone has friends in house? I have a few close friends in the AoB, and nothing to do with COVID, they say it is a ghost town in there. #s are incredibly small. The #s of support teams are tiny compared to what they used to be. If you look at our pipeline, there's nothing for several years (at a minimum) outside of expanded indications for existing products. Nothing more than an educated guess and listening to what others are saying, but seems like we are headed for respiratory being completely gone in a few years, and CV/Met having more of a merge/reduction? It appears like OFEV and Jardiance are the only games in town right now. Would love to see more products on the near horizon for folks to be happy about. Keep your head low and sell I suppose, not much else you can do. Curious on others thoughts?
Click to expand...
Sadly you said it all Respiratory a few years? IDK that even seems a stretch Wonder if the family will sell out human pharma after a while, take the money and run?
 




anonymous said:
I have heard the company is going over to only specialized products upon the sunset of Jardiance. Which has some time-
Maybe another oncology product and very narrow therapeutic areas like OFEV encapsulates.
Not sure how the bio similar market is looking though as soon as a determination is made on how to successfully utilize- shifts will be in that direction - BIPI will likely wait and see how other companies approach such market then approach
Click to expand...
All companies trying to go specialty because much more profitable than mass market PCP drugs with thin margins. The biggest hope for BI sales force is we get to sell Bioequivalent of Humira (a 6 billion $ drug). BI reached settlement and is allowed to launch in the next few years. Havn't heard any buzz about it which is strange. BI may just license to another company as they never seem to have any confidence in their own sales force (spiriva with pfizer, jardiance/tradjenta with Lilly,etc).
 
















Highly specialized seems right. When Jardiance is gone, I don't have a clue what 90% of us would be selling. Thankfully we have a good amount of time with that, but after that, I would expect it will be rough. Even before Jardiance is gone though, I see us being a pretty small company. I think things just haven't played out like senior management wanted. Not sure wtf they were expecting with Stiolto, but clearly that was a dud. If you are in respiratory, you should be looking. You are on borrowed time.

We desperately need new products to sell in the next few years. Looking at our pipeline , there isn't a single thing coming for several years. I understand it though, the days of making a blockbuster primary care drug are few and far between. It is becoming even more rare as time goes by. There are already great medications, that have gone generic in almost every drug class out there.

It's interesting someone mentioned the AOB, I've been with this company a long time and I was at the AOB in December of 2019, ghost town sounds right. Most of the offices are vacant. Huge portions of the Office space has no one at it. I remember saying, wow this feels weird, there is no one here. I worked in house on a rotation 15 years ago and the place was very full. That has to say something. Enjoy Jardiance and push the hell out of it. Great data for it. After Jardiance, get the resumes ready.
 




Whelp, that was a useless call.
Apparently, even the leaders don’t know where the company is going. He was clearly treading water when talking about future pipeline. At least the US government is doing “new” things that will help save us... Here comes the digital therapeutics life boat.
Who’s ready to be an IT company selling data?
 




anonymous said:
Highly specialized seems right. When Jardiance is gone, I don't have a clue what 90% of us would be selling. Thankfully we have a good amount of time with that, but after that, I would expect it will be rough. Even before Jardiance is gone though, I see us being a pretty small company. I think things just haven't played out like senior management wanted. Not sure wtf they were expecting with Stiolto, but clearly that was a dud. If you are in respiratory, you should be looking. You are on borrowed time.

We desperately need new products to sell in the next few years. Looking at our pipeline , there isn't a single thing coming for several years. I understand it though, the days of making a blockbuster primary care drug are few and far between. It is becoming even more rare as time goes by. There are already great medications, that have gone generic in almost every drug class out there.

It's interesting someone mentioned the AOB, I've been with this company a long time and I was at the AOB in December of 2019, ghost town sounds right. Most of the offices are vacant. Huge portions of the Office space has no one at it. I remember saying, wow this feels weird, there is no one here. I worked in house on a rotation 15 years ago and the place was very full. That has to say something. Enjoy Jardiance and push the hell out of it. Great data for it. After Jardiance, get the resumes ready.
Click to expand...
 








AOB is not the barometer, its dead due to covid. Everyone and their dog is working from home. They are adding 300 positions and say they are commited to empowering ppl. BI found out they are tremendously slower than peers in drug development so trying to fix it.
 




anonymous said:
AOB is not the barometer, its dead due to covid. Everyone and their dog is working from home. They are adding 300 positions and say they are commited to empowering ppl. BI found out they are tremendously slower than peers in drug development so trying to fix it.
Click to expand...


There are lots of Respiratory jobs open currently. Smart people are making the move before it’s too late.
 








The company is regressing to a reach and frequency model, while paying lip service to the “Constructive Tension” sales tactics. Is it ZS Associates self serving research, or the US leadership? Using warmed over tactics of the 90’s isn’t going to cure BI’s executive inferiority complex. Granted, BI is using the latest technologies, effective or not, so they are trying. There is much more positive about BI than negative. Regardless, in the last 18 months the leadership attitude seems to have lost its forward focus.
 












anonymous said:
AOB is not the barometer, its dead due to covid. Everyone and their dog is working from home. They are adding 300 positions and say they are commited to empowering ppl. BI found out they are tremendously slower than peers in drug development so trying to fix it.
Click to expand...

The previous poster stated that the AOB was empty when he was there in November of 2019. You said the place was empty because of COVID. Did BI know about the pandemic months before everyone else? No. The place is empty because there are not a need for people who have nothing to do. Face it the company is not what it used to be.
 




anonymous said:
The previous poster stated that the AOB was empty when he was there in November of 2019. You said the place was empty because of COVID. Did BI know about the pandemic months before everyone else? No. The place is empty because there are not a need for people who have nothing to do. Face it the company is not what it used to be.
Click to expand...

^^^. This. So much this. If we are being even remotely honest , the company is on a bare bones skeleton staff and still shrinking at this point. Several key products are going away soon. Nothing at all in our pipeline outside of line extensions. We need new products and we need them badly.
 




Top Bottom
Back
Quote